Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bleomycin + OK-432
- Development stage
- Unknown
- Lead developer
- Chugai Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Small Molecules, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Intralesional
01
Overview
Bleomycin + OK-432 is a combination sclerotherapy regimen investigated for the treatment of parotid salivary fistulas, particularly those refractory to conservative management. Bleomycin is a cytotoxic glycopeptide antibiotic that induces DNA strand breaks and subsequent fibrosis of secretory tissue. OK-432 (Picibanil) is a lyophilized preparation of Streptococcus pyogenes (Group A, type 3) treated with penicillin G, which acts as a biological response modifier. It triggers a localized inflammatory response and cytokine release (such as IL-1, IL-2, and TNF-alpha) via TLR4 activation, promoting the obliteration of the fistula tract. This combination therapy, explored by researchers at Sun Yat-Sen Memorial Hospital, aims to provide a minimally invasive alternative to surgical intervention for salivary gland disorders.
- Brand names
- PicibanilBlenoxane
- Other names
- bleomycin and OK-432bleomycin and Picibanilbleomycin + Picibanil
02
Targets
TLR9 (Toll-like receptor 9)TLR4 (Toll-like receptor 4)DNA
Beyond the preview
Go deeper on bleomycin + OK-432.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bleomycin + OK-432.